An overview of COVID-19 in solid organ transplantation

Bartelt, Luther A.; Duin, David van

doi:10.1016/j.cmi.2022.02.005

Cited by 15 publications

(11 citation statements)

References 85 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Introductionmentioning

confidence: 99%

“…The field of organ transplantation has been severely affected in the era of COVID-19 ( 4 ). Most of the SOT centers have experienced a significant decline in transplant activity given a variety of factors, such as limited donor pools, extensive SARS-CoV-2 testing, and decreased intensive care unit (ICU) capacities ( 4 , 5 ). Lung transplantations were associated with a number of donor-derived COVID-19 infections which raised the urge to set novel guidelines for the prevention and treatment of LuTx recipients ( 4 , 5 ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Vaccination Against SARS-CoV-2 in Lung Transplant Recipients: Immunogenicity, Efficacy and Safety

et al. 2022

View full text Add to dashboard Cite

Lung transplant (LuTx) recipients are considered to be at higher risk of developing serious illness from COVID-19. COVID-19 vaccines were shown in randomized clinical trials to substantially reduce the severity of COVID-19, however, patients receiving immunosuppressants were excluded from these trials. Observational studies report a proportion of solid organ transplant (SOT) recipients being able to mount sufficient titers of SARS-CoV-2 specific IgG antibodies, however, other studies demonstrate that more than 90% of the SOT recipients elicit neither humoral nor cellular immune response after vaccination. Currently, the third booster dose of the COVID-19 vaccines was shown to elicit strong immune responses and may, thus, represent a potent tool in the prevention of severe COVID-19 infection in SOT recipients, including patients after lung transplantation. To address the main challenges of SARS-CoV-2 vaccination in LuTx recipients in the era of COVID-19, we have closely collected all available data on the immunogenicity, efficacy and safety of COVID-19 vaccines in LuTx recipients.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Vaccination Against SARS-CoV-2 in Lung Transplant Recipients: Immunogenicity, Efficacy and Safety

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Several studies suggested that transplant patients show a better immune response to mRNA-based vaccines than to adenovirustype vector vaccines. Although antibody responses are significantly lower in transplant patients with COVID-19 in contrast to the general population, some studies showed that vaccination could help in the reduction of up to 80% of COVID-19 incidences in transplant patients [30][31][32].…”

Section: Precautions While Accepting Organs During the Covid-19 Pandemicmentioning

confidence: 99%

COVID-19 and organ transplant recipients, risk factors and considerations: A mini-review

Saleh¹,

Sharif²,

Sharif³

et al. 2022

Int. J. Biol. Pharm. Sci. Arch.

View full text Add to dashboard Cite

The emergence of coronavirus 2 is distinctive and created an unprecedented obstacle in the entire history of organ transplantation. Transplant patients are more susceptible to COVID-19 infection due to various medical comorbidities and immunosuppressive therapy. The mortality rate was also reported as up to 30% in transplant patients. The fundamental implications of COVID-19 are different depending on the organ transplanted and the receiver's comorbidities. In addition to this, non-pharmacological interventions and vaccines help prevent COVID-19 in transplant patients. In this mini-review, we focused on summarizing current literature associated with transplant patients with COVID-19 infection, clinical outcomes, risk factors, and precautions to be taken during the pandemic.

show abstract

“…Although the COVID-19 pandemic is likely to move to an endemic phase, with vaccination and novel therapeutic options potentially reducing infection rates in SOT recipients [11][12][13], there are still limited data on the risk of poor outcomes and progression of SARS-CoV-2 infection, response to vaccination, or efficacy of monoclonal antibody therapy in SOT. Therefore, an updated review of recently published relevant studies addressing these aspects is here presented.…”

Section: Introductionmentioning

confidence: 99%

Reduction in the risk of progression of solid organ transplant recipients infected by SARS-CoV-2 treated with monoclonal antibodies

Candel¹,

Salavert²,

Mingot³

et al. 2023

Rev Esp Quimioter

View full text Add to dashboard Cite

Recipients of solid organ transplants (SOT) are at higher risk of infection by SARS-CoV-2 virus especially due to chronic immunosuppression therapy and frequent multiple comorbid conditions. COVID-19 is a potentially life-threatening disease in SOT recipients, with an increased likelihood of progressing to severe disease, with the need of hospitalization, admission to the intensive care unit (ICU) and mechanical ventilatory support. This article presents an updated review of different aspects related to the outcome of COVID-19 in SOT recipients. In nvaccinated SOT recipients, COVID-19 is associated with a high mortality rate, in-patient care and ICU admission, and impaired graft function or rejection in severe disease. In vaccinated SOT recipients even after full vaccination, there is a reduction of the risk of mortality, but the course of COVID-19 may continue to be severe, influenced by the time from transplant, the net state of immunosuppression and having suffered graft rejection or dysfunction. SOT recipients develop lower immunity from mRNA vaccines with suboptimal response. Treatment with mAbs provides favorable outcomes in non-hospitalized SOT recipients at high risk for severe disease, with lower rates of hospitalization, emergency department visits, ICU care, progression to severe disease, and death. However, broad vaccination and therapeutic options are required, particularly in light of the tendency of the SARS-CoV-2 virus to adapt and evade both natural and vaccine-induced immunity.

show abstract

An overview of COVID-19 in solid organ transplantation

Cited by 15 publications

References 85 publications

Vaccination Against SARS-CoV-2 in Lung Transplant Recipients: Immunogenicity, Efficacy and Safety

Vaccination Against SARS-CoV-2 in Lung Transplant Recipients: Immunogenicity, Efficacy and Safety

COVID-19 and organ transplant recipients, risk factors and considerations: A mini-review

Reduction in the risk of progression of solid organ transplant recipients infected by SARS-CoV-2 treated with monoclonal antibodies

Contact Info

Product

Resources

About